Tibet AIM Pharm. Inc.
SZSE:002826.SZ
10.97 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 667.039 | 856.734 | 725.459 | 602.619 | 553.255 | 488.774 | 380.293 | 451.922 | 346.995 | 290.726 | 221.108 |
Cost of Revenue
| 325.588 | 480.56 | 464.955 | 385.895 | 370.922 | 332.665 | 108.8 | 131.548 | 107.246 | 102.265 | 90.84 |
Gross Profit
| 341.451 | 376.174 | 260.504 | 216.725 | 182.334 | 156.109 | 271.492 | 320.374 | 239.749 | 188.461 | 130.268 |
Gross Profit Ratio
| 0.512 | 0.439 | 0.359 | 0.36 | 0.33 | 0.319 | 0.714 | 0.709 | 0.691 | 0.648 | 0.589 |
Reseach & Development Expenses
| 13.711 | 13.354 | 11.39 | 6.848 | 4.997 | 16.409 | 3.593 | 2.177 | 5.541 | 7.472 | 11.138 |
General & Administrative Expenses
| 26.316 | 24.7 | 29.249 | 18.496 | 18.517 | 13.06 | 14.096 | 19.979 | 16.505 | 10.934 | 12.684 |
Selling & Marketing Expenses
| 247.337 | 270.673 | 172.566 | 142.871 | 111.457 | 99.184 | 182.156 | 215.958 | 155.534 | 123.481 | 82.623 |
SG&A
| 273.653 | 295.373 | 201.815 | 161.368 | 129.974 | 112.243 | 196.251 | 235.937 | 172.04 | 134.416 | 95.307 |
Other Expenses
| 0.095 | 11.288 | 4.702 | 3.405 | -0.039 | 2.137 | 2.816 | 16.52 | 11.523 | 12.62 | 12.104 |
Operating Expenses
| 310.135 | 320.015 | 217.908 | 171.62 | 134.932 | 131.083 | 205.334 | 263.308 | 191.833 | 156.105 | 117.975 |
Operating Income
| 23.505 | 55.729 | 48.637 | 43.126 | 47.704 | 26.857 | 65.101 | 47.152 | 45.458 | 29.965 | 14.238 |
Operating Income Ratio
| 0.035 | 0.065 | 0.067 | 0.072 | 0.086 | 0.055 | 0.171 | 0.104 | 0.131 | 0.103 | 0.064 |
Total Other Income Expenses Net
| 0.095 | 0.973 | 1.376 | 4.222 | 0.034 | 3.966 | 1.759 | 6.13 | 8.203 | 10.178 | 13.902 |
Income Before Tax
| 23.6 | 56.703 | 50.013 | 47.348 | 47.737 | 28.993 | 67.917 | 63.197 | 56.119 | 42.534 | 26.195 |
Income Before Tax Ratio
| 0.035 | 0.066 | 0.069 | 0.079 | 0.086 | 0.059 | 0.179 | 0.14 | 0.162 | 0.146 | 0.118 |
Income Tax Expense
| 7.874 | 10.587 | 6.54 | 6.257 | 10.408 | 3.738 | 7.44 | 7.839 | 6.089 | 8.678 | 4.371 |
Net Income
| 15.386 | 44.135 | 42.476 | 41.091 | 37.329 | 25.255 | 60.477 | 55.358 | 50.03 | 32.373 | 19.707 |
Net Income Ratio
| 0.023 | 0.052 | 0.059 | 0.068 | 0.067 | 0.052 | 0.159 | 0.122 | 0.144 | 0.111 | 0.089 |
EPS
| 0.08 | 0.23 | 0.22 | 0.22 | 0.2 | 0.13 | 0.32 | 0.38 | 0.37 | 0.24 | 0.39 |
EPS Diluted
| 0.08 | 0.23 | 0.22 | 0.22 | 0.2 | 0.13 | 0.32 | 0.38 | 0.37 | 0.24 | 0.39 |
EBITDA
| 60.541 | 83.694 | 70.571 | 67.571 | 59.982 | 40.517 | 80.745 | 79.598 | 63.359 | 48.876 | 31.015 |
EBITDA Ratio
| 0.091 | 0.098 | 0.097 | 0.112 | 0.108 | 0.083 | 0.212 | 0.176 | 0.183 | 0.168 | 0.14 |